Rahul Banerjee, Associate Professor UW Medicine and Fred Hutch Cancer Center, shared on X:
“Pleasure learning from Louis Williams, an expert in both myeloma and AI!
Part 1 of our two-part ‘AI in blood cancers’ podcast: How routine clinical care will shift, e.g.
Part 2 (stay tuned): Research-focused… with AIs like this, can we finally get rid of CROs?
‘If we’re talking about big themes and not just use cases, one theme that I see. talking to these collaboration partners and some of my own research and going to conferences and just looking at what people are publishing is I think in the future, I may be wrong, but I think in the future we may see a shift from episodic care to more metronomic care, meaning that we’re going to be getting…
Our paradigm now is we round on a patient, we make a decision, or we have a visit with a patient, we decide on a course of treatment, and we leave. And then we see the patient again obviously, and we check results, and we see how the patient’s doing.
I think we may be collecting more data. We may be using real-time or at-home monitoring tools, especially if you think about in the context of cellular therapies. And we may go for more of a, over time, I think, a metronomic approach where we’re constantly being fed and making decisions on patient data that is outside of the paradigm of our episodic visits. So, that would be something to keep an eye on more in the longer term.’ ”
Hannah Abrams, Fellow, Hematology and Oncology at University of Washington, added:
“How should we reimburse health systems for ‘metronomic‘ – high frequency, small quantity – cancer care?
G2211 is a start toward this but doesn’t really capture the work that goes into being so constantly available and reviewing someone’s data.”
You may also be interested in:
C. Ola Landgren: Keynote Spotlight on AI in Myeloma Research
